{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:38:15Z","timestamp":1786523895954,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ebiom.2026.106397","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:50:28Z","timestamp":1785196228000},"page":"106397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumour cell density quantified by artificial intelligence is associated with differential benefit from irinotecan-based chemo-radiotherapy in locally advanced rectal cancer: a post-hoc study of the phase 3 ARISTOTLE trial"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8806-1379","authenticated-orcid":false,"given":"Zhuoyan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Royle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sebag-Montefiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-8795","authenticated-orcid":false,"given":"Charles-Antoine","family":"Collins Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-0628","authenticated-orcid":false,"given":"Maria A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib2","first-page":"36","article-title":"Biomarkers in locally advanced rectal cancer: a review","volume":"21","author":"Mendis","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106397_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-2007-984870","article-title":"Management of locally advanced primary and recurrent rectal cancer","volume":"20","author":"de Wilt","year":"2007","journal-title":"Clin Colon Rectal Surg"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106397_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106397_bib5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-016-0740-2","article-title":"Tumor-associated stromal cells as key contributors to the tumor microenvironment","volume":"18","author":"Bussard","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106397_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","article-title":"Hallmarks of cancer: interactions with the tumor stroma","volume":"316","author":"Pietras","year":"2010","journal-title":"Exp Cell Res"},{"issue":"42","key":"10.1016\/j.ebiom.2026.106397_bib11","doi-asserted-by":"crossref","first-page":"68954","DOI":"10.18632\/oncotarget.12135","article-title":"Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2026.106397_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X21989686","article-title":"Standardized assessment of the tumor-stroma ratio in colorectal cancer: interobserver validation and reproducibility of a potential prognostic factor","volume":"14","author":"Souza da Silva","year":"2021","journal-title":"Clin Pathol"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106397_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00428-018-2408-z","article-title":"Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations","volume":"473","author":"van Pelt","year":"2018","journal-title":"Virchows Arch"},{"issue":"47","key":"10.1016\/j.ebiom.2026.106397_bib14","doi-asserted-by":"crossref","first-page":"77565","DOI":"10.18632\/oncotarget.12723","article-title":"Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial","volume":"7","author":"Hale","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106397_bib15","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/sj.bjc.6605674","article-title":"The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients","volume":"102","author":"West","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s44276-025-00123-8","article-title":"Deep-learning enabled combined measurement of tumour cell density and tumour infiltrating lymphocyte density as a prognostic biomarker in colorectal cancer","volume":"3","author":"Westwood","year":"2025","journal-title":"BJC Rep"},{"issue":"15 Suppl","key":"10.1016\/j.ebiom.2026.106397_bib7","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1200\/JCO.2020.38.15_suppl.4101","article-title":"ARISTOTLE: a phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC)","volume":"38","author":"Sebag-Montefiore","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106397_bib17","first-page":"6105","article-title":"EfficientNet: rethinking model scaling for convolutional neural networks","volume":"97","author":"Tan","year":"2019","journal-title":"Proc Mach Learn Res"},{"key":"10.1016\/j.ebiom.2026.106397_bib18","series-title":"100,000 Histological Images of Human Colorectal Cancer and Healthy Tissue [dataset]","author":"Kather","year":"2018"},{"key":"10.1016\/j.ebiom.2026.106397_bib19","series-title":"Lecture Notes in Computer Science","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-55088-1_10","article-title":"SoftCTM: cell detection by soft instance segmentation and consideration of cell-tissue interaction","author":"Schoenpflug","year":"2024"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106397_bib20","first-page":"291","article-title":"Quantification of histochemical staining by color deconvolution","volume":"23","author":"Ruifrok","year":"2001","journal-title":"Anal Quant Cytol Histol"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106397_bib21","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1109\/TMI.2018.2820199","article-title":"Whole-slide mitosis detection in H&E breast histology using PHH3 as a reference to train distilled stain-invariant convolutional networks","volume":"37","author":"Tellez","year":"2018","journal-title":"IEEE Trans Med Imaging"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106397_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/path.6376","article-title":"Tumour purity assessment with deep learning in colorectal cancer and impact on molecular analysis","volume":"256","author":"Schoenpflug","year":"2022","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106397_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001717","article-title":"Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer","volume":"9","author":"Wilkins","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106397_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100738","article-title":"Prognostic value of tumor-stroma ratio in a screened stage II colon cancer population: intratumoral site-specific assessment and tumor budding synergy","volume":"38","author":"Kristensen","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ebiom.2026.106397_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101862","article-title":"Tumour-stroma ratio to predict pathological response to neo-adjuvant treatment in rectal cancer","volume":"45","author":"Strous","year":"2022","journal-title":"Surg Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib26","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1186\/s12885-021-08516-x","article-title":"The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study","volume":"21","author":"Liang","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106397_bib27","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/curroncol29050263","article-title":"Tumor stroma ratio and its significance in locally advanced colorectal cancer","volume":"29","author":"Sullivan","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ebiom.2026.106397_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.738080","article-title":"Impact of tumor\u2013stroma ratio on the prognosis of colorectal cancer: a systematic review","volume":"11","author":"Gao","year":"2021","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106397_bib29","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1245\/s10434-019-07931-6","article-title":"The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer","volume":"26","author":"van Wyk","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ebiom.2026.106397_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105228","article-title":"Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGF\u03b2 as key predictors","volume":"106","author":"Domingo","year":"2024","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106397_bib32","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/2767-9764.CRC-23-0502","article-title":"Stratification to neoadjuvant radiotherapy in rectal cancer by regimen and transcriptional signatures","volume":"4","author":"Mahmood","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106397_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41698-024-00580-3","article-title":"Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy","volume":"8","author":"Lafarge","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ebiom.2026.106397_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103054","article-title":"Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer","volume":"61","author":"Zhao","year":"2020","journal-title":"eBioMedicine"},{"issue":"36","key":"10.1016\/j.ebiom.2026.106397_bib34","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1200\/JCO.20.01932","article-title":"Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer","volume":"38","author":"Zhu","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106397_bib35","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cac2.70058","article-title":"Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial","volume":"45","author":"Zhang","year":"2025","journal-title":"Cancer Commun"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:19:11Z","timestamp":1786522751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S2352396426002811"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106397","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour cell density quantified by artificial intelligence is associated with differential benefit from irinotecan-based chemo-radiotherapy in locally advanced rectal cancer: a post-hoc study of the phase 3 ARISTOTLE trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106397"}}